-
Je něco špatně v tomto záznamu ?
Phosphodiesterase 1 regulation is a key mechanism in vascular aging
PK. Niño, M. Durik, AH. Danser, R. de Vries, UM. Musterd-Bhaggoe, ME. Meima, M. Kavousi, M. Ghanbari, JH. Hoeijmakers, CJ. O'Donnell, N. Franceschini, GM. Janssen, JG. De Mey, Y. Liu, CM. Shanahan, OH. Franco, A. Dehghan, AJ. Roks,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26464516
DOI
10.1042/cs20140753
Knihovny.cz E-zdroje
- MeSH
- arteriae carotides enzymologie patologie MeSH
- celogenomová asociační studie MeSH
- cyklické nukleotidfosfodiesterasy, typ 1 antagonisté a inhibitory genetika metabolismus MeSH
- cyklické nukleotidfosfodiesterasy, typ 5 genetika metabolismus MeSH
- DNA vazebné proteiny nedostatek genetika MeSH
- endonukleasy nedostatek genetika MeSH
- fenotyp MeSH
- genetická predispozice k nemoci MeSH
- guanosinmonofosfát cyklický metabolismus MeSH
- hydrolýza MeSH
- hyperplazie MeSH
- hypertenze enzymologie genetika patofyziologie MeSH
- inhibitory fosfodiesterasy 5 farmakologie MeSH
- intimomediální šíře tepenné stěny MeSH
- jednonukleotidový polymorfismus MeSH
- krevní tlak MeSH
- kultivované buňky MeSH
- lidé MeSH
- myocyty hladké svaloviny účinky léků enzymologie MeSH
- myši inbrední C57BL MeSH
- myši knockoutované MeSH
- nemoci arterie carotis enzymologie genetika patologie MeSH
- regulace genové exprese u nádorů MeSH
- stárnutí buněk MeSH
- stárnutí genetika metabolismus MeSH
- svaly hladké cévní účinky léků enzymologie MeSH
- systémy druhého messengeru MeSH
- techniky in vitro MeSH
- vazodilatace * účinky léků MeSH
- vazodilatancia farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of genomic instability, a primary causal factor in aging, on vascular smooth muscle cells (VSMCs) and that the underlying mechanism plays a role in human age-related vascular disease. To test our hypothesis, we combined experiments in mice with genomic instability resulting from the defective nucleotide excision repair gene ERCC1 (Ercc1(d/-) mice), human VSMC cultures and population genome-wide association studies (GWAS). Aortic rings of Ercc1(d/-) mice showed 43% reduced responses to the soluble guanylate cyclase (sGC) stimulator sodium nitroprusside (SNP). Inhibition of phosphodiesterase (PDE) 1 and 5 normalized SNP-relaxing effects in Ercc1(d/-) to wild-type (WT) levels. PDE1C levels were increased in lung and aorta. cGMP hydrolysis by PDE in lungs was higher in Ercc1(d/-) mice. No differences in activity or levels of cGMP-dependent protein kinase 1 or sGC were observed in Ercc1(d/-) mice compared with WT. Senescent human VSMC showed elevated PDE1A and PDE1C and PDE5 mRNA levels (11.6-, 9- and 2.3-fold respectively), which associated with markers of cellular senescence. Conversely, PDE1 inhibition lowered expression of these markers. Human genetic studies revealed significant associations of PDE1A single nucleotide polymorphisms with diastolic blood pressure (DBP; β=0.28, P=2.47×10(-5)) and carotid intima-media thickness (cIMT; β=-0.0061, P=2.89×10(-5)). In summary, these results show that genomic instability and cellular senescence in VSMCs increase PDE1 expression. This might play a role in aging-related loss of vasodilator function, VSMC senescence, increased blood pressure and vascular hypertrophy.
Cardiovascular Division James Black Centre King's College London SE5 9NU U K
Department of Epidemiology Erasmus MC Rotterdam 3015 CN The Netherlands
Department of Epidemiology University of North Carolina Chapel Hill Chapel Hill NC 27599 7435 U S A
Department of Genetics Erasmus MC Rotterdam 3015 CN The Netherlands
Department of Pharmacology Maastricht University 6211 LK The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000014
- 003
- CZ-PrNML
- 005
- 20160122125132.0
- 007
- ta
- 008
- 160108s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1042/CS20140753 $2 doi
- 035 __
- $a (PubMed)26464516
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Niño, Paula K Bautista $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 245 10
- $a Phosphodiesterase 1 regulation is a key mechanism in vascular aging / $c PK. Niño, M. Durik, AH. Danser, R. de Vries, UM. Musterd-Bhaggoe, ME. Meima, M. Kavousi, M. Ghanbari, JH. Hoeijmakers, CJ. O'Donnell, N. Franceschini, GM. Janssen, JG. De Mey, Y. Liu, CM. Shanahan, OH. Franco, A. Dehghan, AJ. Roks,
- 520 9_
- $a Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of genomic instability, a primary causal factor in aging, on vascular smooth muscle cells (VSMCs) and that the underlying mechanism plays a role in human age-related vascular disease. To test our hypothesis, we combined experiments in mice with genomic instability resulting from the defective nucleotide excision repair gene ERCC1 (Ercc1(d/-) mice), human VSMC cultures and population genome-wide association studies (GWAS). Aortic rings of Ercc1(d/-) mice showed 43% reduced responses to the soluble guanylate cyclase (sGC) stimulator sodium nitroprusside (SNP). Inhibition of phosphodiesterase (PDE) 1 and 5 normalized SNP-relaxing effects in Ercc1(d/-) to wild-type (WT) levels. PDE1C levels were increased in lung and aorta. cGMP hydrolysis by PDE in lungs was higher in Ercc1(d/-) mice. No differences in activity or levels of cGMP-dependent protein kinase 1 or sGC were observed in Ercc1(d/-) mice compared with WT. Senescent human VSMC showed elevated PDE1A and PDE1C and PDE5 mRNA levels (11.6-, 9- and 2.3-fold respectively), which associated with markers of cellular senescence. Conversely, PDE1 inhibition lowered expression of these markers. Human genetic studies revealed significant associations of PDE1A single nucleotide polymorphisms with diastolic blood pressure (DBP; β=0.28, P=2.47×10(-5)) and carotid intima-media thickness (cIMT; β=-0.0061, P=2.89×10(-5)). In summary, these results show that genomic instability and cellular senescence in VSMCs increase PDE1 expression. This might play a role in aging-related loss of vasodilator function, VSMC senescence, increased blood pressure and vascular hypertrophy.
- 650 _2
- $a stárnutí $x genetika $x metabolismus $7 D000375
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní tlak $7 D001794
- 650 _2
- $a arteriae carotides $x enzymologie $x patologie $7 D002339
- 650 _2
- $a nemoci arterie carotis $x enzymologie $x genetika $x patologie $7 D002340
- 650 _2
- $a intimomediální šíře tepenné stěny $7 D059168
- 650 _2
- $a stárnutí buněk $7 D016922
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a guanosinmonofosfát cyklický $x metabolismus $7 D006152
- 650 _2
- $a cyklické nukleotidfosfodiesterasy, typ 1 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D054677
- 650 _2
- $a cyklické nukleotidfosfodiesterasy, typ 5 $x genetika $x metabolismus $7 D054706
- 650 _2
- $a DNA vazebné proteiny $x nedostatek $x genetika $7 D004268
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a endonukleasy $x nedostatek $x genetika $7 D004720
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a celogenomová asociační studie $7 D055106
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrolýza $7 D006868
- 650 _2
- $a hyperplazie $7 D006965
- 650 _2
- $a hypertenze $x enzymologie $x genetika $x patofyziologie $7 D006973
- 650 _2
- $a techniky in vitro $7 D066298
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a myši knockoutované $7 D018345
- 650 _2
- $a svaly hladké cévní $x účinky léků $x enzymologie $7 D009131
- 650 _2
- $a myocyty hladké svaloviny $x účinky léků $x enzymologie $7 D032389
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a inhibitory fosfodiesterasy 5 $x farmakologie $7 D058986
- 650 _2
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a systémy druhého messengeru $7 D015290
- 650 12
- $a vazodilatace $x účinky léků $7 D014664
- 650 _2
- $a vazodilatancia $x farmakologie $7 D014665
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Durik, Matej $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic.
- 700 1_
- $a Danser, A H Jan $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a de Vries, René $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Musterd-Bhaggoe, Usha M $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Meima, Marcel E $u Department of Internal Medicine, Division of Endocrinology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Kavousi, Maryam $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Ghanbari, Mohsen $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Hoeijmakers, Jan H $u Department of Genetics, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a O'Donnell, Christopher J $u National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA 01702-5827, U.S.A. National Heart, Lung, and Blood Institute, Bethesda, MD 20892, U.S.A. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, U.S.A.
- 700 1_
- $a Franceschini, Nora $u Department of Epidemiology, University of North Carolina Chapel Hill, Chapel Hill, NC 27599-7435, U.S.A.
- 700 1_
- $a Janssen, Ger M J $u Department of Pharmacology, Maastricht University, 6211 LK, The Netherlands.
- 700 1_
- $a De Mey, Jo G R $u Department of Pharmacology, Maastricht University, 6211 LK, The Netherlands Department of Cardiovascular and Renal research, Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.
- 700 1_
- $a Liu, Yiwen $u Cardiovascular Division, James Black Centre, King's College, London SE5 9NU, U.K.
- 700 1_
- $a Shanahan, Catherine M $u Cardiovascular Division, James Black Centre, King's College, London SE5 9NU, U.K.
- 700 1_
- $a Franco, Oscar H $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Dehghan, Abbas $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
- 700 1_
- $a Roks, Anton J M $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands a.roks@erasmusmc.nl.
- 773 0_
- $w MED00009494 $t Clinical science (London, England 1979) $x 1470-8736 $g Roč. 129, č. 12 (2015), s. 1061-75
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26464516 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160122125252 $b ABA008
- 999 __
- $a ok $b bmc $g 1102295 $s 924220
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 129 $c 12 $d 1061-75 $e 20150625 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494
- LZP __
- $a Pubmed-20160108